Azenta, Inc. (AZTA)

What does Azenta do?

Azenta is a life sciences company that built its reputation solving one of the trickiest problems in research and drug development: how to store, track, and preserve biological samples at extreme cold. The company provides automated systems that maintain samples at ultra-low temperatures, along with the software and logistics to manage them across labs, biobanks, hospitals, and pharma facilities worldwide. Their equipment and storage solutions sit at the heart of drug discovery pipelines, clinical trials, and advanced cell therapy work.

How did the company get here?

Azenta traces its roots to Brooks Automation, founded in 1978 in Massachusetts. For decades, the company built automation equipment for semiconductor manufacturers—factory robots, material handling systems, the precision machinery that moves components in chip plants. In 2021, Brooks made a major pivot, spinning off or selling the semiconductor business and renaming itself Azenta to signal a complete reorientation toward life sciences. That shift reflected both where the growth was and where the company’s engineering expertise could command premium prices: the explosion in biotech funding and the globalization of sample analysis meant demand for cold-chain infrastructure was soaring.

Where’s the money?

Azenta operates two main business lines. Sample Management Solutions generates revenue from the sale of cryogenic storage systems, automated storage and retrieval equipment, sample handling consumables, and recurring service contracts for maintenance and monitoring. Multiomics, its acquired services division, brings in revenue from laboratory analysis work—gene sequencing, gene synthesis, and related profiling services sold on a per-sample or per-project basis. The recurring nature of service contracts and consumables provides a stable revenue floor, while the Multiomics side scales with client demand for analysis.

Who buys from Azenta?

The customer base spans global pharmaceutical and biotech companies, academic research institutions, clinical laboratories, and healthcare providers. Pharma and biotech firms use Azenta’s systems to manage thousands of samples as they move through drug discovery and development. Large biobanks and university research centers rely on the company for storing irreplaceable samples. The company operates across North America, Europe, Asia-Pacific, and China, serving customers in markets where life sciences R&D is most concentrated and where sample preservation demands are highest.

What makes this different from competitors?

The space isn’t crowded in the way that, say, software-as-a-service is. Azenta competes with specialized equipment makers and a handful of other cold-chain automation vendors, but the company has built significant switching costs through its integrated approach—combining hardware (cryogenic systems), software (tracking and management), consumables (sample tubes and vials), and increasingly, services (the Multiomics analysis). Once a lab commits to one vendor’s system, migrating samples and workflows to a competitor is expensive and risky. That integration and the legacy of engineering know-how from the automation business are durable competitive edges.